In: NEOPLASMA, vol. 61, no. 4
Y. Zhang - M. Liu - H. Yang - J. Wang - H. Liu - X. Li - J. Li - J. Xu
Detaily:
Rok, strany: 2014, 461 - 467
O článku:
This study proposed to investigate the relationship of PIK3CA somatic mutations, the most commonactivating mutations in human breast cancer (BC), and the efficacy of neoadjuvant chemotherapy(NCT).Using a novel liquidchip technology, PIK3CA DNA somat ic mutations and HER2, PTEN,EGFR mRNA expression profiles were analyzed in formalin fixed paraffin embedded samples of 93. Keywords: PIK3CA somatic mutation, NCT, breast cancer, epirubicin, docetaxel
Ako citovať:
ISO 690:
Zhang, Y., Liu, M., Yang, H., Wang, J., Liu, H., Li, X., Li, J., Xu, J. 2014. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer. In NEOPLASMA, vol. 61, no.4, pp. 461-467. 0028-2685.
APA:
Zhang, Y., Liu, M., Yang, H., Wang, J., Liu, H., Li, X., Li, J., Xu, J. (2014). PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer. NEOPLASMA, 61(4), 461-467. 0028-2685.